Company intelligence / Profile preview

Tetraneuron

Ownership: Private
Development stage: Preclinical

Overview

Tetraneuron is developing innovative gene therapies for neurodegenerative diseases, primarily Alzheimer’s disease. Their lead program targets the pathogenic phosphorylation of the E2F4 transcription factor to reinstate biological processes affected in these conditions. The company has completed method validation and proof-of-concept studies, is in the preclinical regulatory phase, and has held a pre-IND meeting with the FDA as of 2023. They have also developed a patented method for early risk assessment of Alzheimer’s disease

Therapeutic areas: Neurology
Modalities: Gene therapies (specifically gene therapy targeting E2F4DN)
Industry: Biotech

Drug pipeline

1 asset

TET-101

Pre-clinical

Indications: Alzheimer's disease

Partnerships

Johnson & Johnson Innovation/JLABS incubator participant

Beyond the preview

Go deeper on Tetraneuron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetraneuron.

Explore the full profile